GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma

Phase 3

Completed

Conditions: Bronchial Asthma

Interventions: Drug: GW815SF HFA MDI
Drug: salmeterol and fluticasone propionate

First Posted Date: 2007-03-16

Last Posted Date: 2010-06-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 51

Registration Number: NCT00448435

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

A Study Of New Medicine (GSK 372475) For The Treatment Of Depression

Phase 2

Completed

Conditions: Depressive Disorder

Interventions: Drug: placebo
Drug: GSK372475
Drug: venlafaxine

First Posted Date: 2007-03-15

Last Posted Date: 2014-10-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 396

Registration Number: NCT00448058

Locations: 🇿🇦
GSK Investigational Site, Vereeniging, South Africa

A Study of GW842166 in Adults With Osteoarthritis Pain

Phase 2

Completed

Conditions: Osteoarthritis, Knee

First Posted Date: 2007-03-14

Last Posted Date: 2009-05-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 308

Registration Number: NCT00447486

Locations: 🇸🇪
GSK Investigational Site, Upplands Väsby, Sweden

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

Phase 2

Terminated

Conditions: Cancer

Interventions: Drug: Oral lapatinib tablets or placebo tablets

First Posted Date: 2007-03-14

Last Posted Date: 2012-06-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 32

Registration Number: NCT00447226

Locations: 🇺🇸
GSK Investigational Site, Vancouver, Washington, United States

This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an Antigen Challenge

Phase 2

Completed

Conditions: Asthma

First Posted Date: 2007-03-09

Last Posted Date: 2012-06-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT00445510

Locations: 🇳🇿
GSK Investigational Site, Wellington, New Zealand

Dental Pain 3rd Molar Tooth Extraction GW842166

Phase 2

Completed

Conditions: Pain

First Posted Date: 2007-03-08

Last Posted Date: 2009-05-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 112

Registration Number: NCT00444769

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Single Dose GW685698X Magnesium Stearate Study In Asthmatic Patients.

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: GW685698X
Drug: GW685698X containing magnesium stearate

First Posted Date: 2007-03-07

Last Posted Date: 2017-08-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT00444509

Locations: 🇳🇿
GSK Investigational Site, Wellington, New Zealand

A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects
Anaemia

First Posted Date: 2007-03-05

Last Posted Date: 2012-03-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 90

Registration Number: NCT00443170

Locations: 🇦🇺
GSK Investigational Site, Adelaide, South Australia, Australia

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

Phase 1

Completed

Conditions: Purpura, Thrombocytopaenic, Idiopathic

Interventions: Drug: eltrombopag

First Posted Date: 2007-03-05

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 29

Registration Number: NCT00442871

Locations: 🇺🇸
GSK Investigational Site, Saint Paul, Minnesota, United States

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

Phase 3

Completed

Conditions: Thrombosis, Venous

Interventions: Drug: Fondaparinux 2.5mg or placebo

First Posted Date: 2007-03-05

Last Posted Date: 2017-03-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 3002

Registration Number: NCT00443053

Locations: 🇺🇦
GSK Investigational Site, Zaporizhzhya, Ukraine

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy